-
1.发明授权Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases 有权三唑并吡啶类作为治疗皮肤疾病的磷酸二酯酶抑制剂公开(公告)号：US08952162B2
公开(公告)日：2015-02-10
申请号：US13140505
申请日：2009-12-18
IPC分类号： C07D471/04 , A61K31/437
CPC分类号： C07D471/04
摘要： The present invention relates to a compound according to formula I, wherein R1, R2 and A are as defined herein, which exhibit PDE4 inhibitory activity and may be used in the treatment of inflammatory diseases or autoimmune diseases, in particular inflammatory or proliferative dermal diseases.
摘要翻译： 本发明涉及式I化合物，其中R 1，R 2和A如本文所定义，其表现出PDE4抑制活性，并且可用于治疗炎性疾病或自身免疫性疾病，特别是炎性或增殖性皮肤疾病。
-
2.发明申请TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES 有权作为磷酸二酯酶抑制剂治疗牙齿疾病的三唑吡啶公开(公告)号：US20120028974A1
公开(公告)日：2012-02-02
申请号：US13140505
申请日：2009-12-18
IPC分类号： A61K31/437 , C07D413/14 , A61K31/506 , A61K31/5377 , A61K31/501 , A61K31/496 , A61P35/00 , A61P29/00 , A61P17/06 , A61P17/14 , A61Q19/08 , A61P17/10 , A61P17/00 , A61P17/04 , A61P17/02 , A61P17/08 , C07D471/04
CPC分类号： C07D471/04
摘要： The present invention relates to a compound according to formula I, wherein R1, R2 and A are as defined herein, which exhibit PDE4 inhibitory activity and may be used in the treatment of inflammatory diseases or autoimmune diseases, in particular inflammatory or proliferative dermal diseases.
摘要翻译： 本发明涉及式I化合物，其中R 1，R 2和A如本文所定义，其表现出PDE4抑制活性，并且可用于治疗炎性疾病或自身免疫性疾病，特别是炎性或增殖性皮肤疾病。
-
3.发明申请公开(公告)号：US20140303150A1
公开(公告)日：2014-10-09
申请号：US13996989
申请日：2011-12-22
申请人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
发明人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
IPC分类号： C07D513/04 , C07D333/38 , C07D471/04 , C07D401/04 , C07D265/36 , C07D405/06 , C07D271/08 , C07D277/587 , C07D295/205 , C07D307/00 , C07D307/94
CPC分类号： C07D261/18 , A61K31/365 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/472 , A61K31/502 , A61K31/5375 , A61K31/538 , C07C271/34 , C07C271/36 , C07C271/38 , C07C2603/86 , C07D209/08 , C07D209/42 , C07D213/79 , C07D215/50 , C07D217/26 , C07D231/14 , C07D231/56 , C07D233/90 , C07D237/28 , C07D239/28 , C07D249/04 , C07D249/06 , C07D261/20 , C07D263/34 , C07D265/36 , C07D271/08 , C07D277/32 , C07D277/56 , C07D277/587 , C07D295/182 , C07D295/205 , C07D295/21 , C07D307/00 , C07D307/68 , C07D307/94 , C07D309/08 , C07D333/38 , C07D333/40 , C07D401/04 , C07D405/06 , C07D471/04 , C07D493/08 , C07D495/04 , C07D513/04
摘要： The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
摘要翻译： 本发明涉及通式I的化合物，其中R是任选被R 7取代的杂芳基; 或R是任选被R 8取代的杂环烷基或杂环烯基; 或R为X，其中X为-NR 11 R 12; 其药学上可接受的盐，水合物或溶剂合物，用于单独或与一种或多种其它药学活性化合物组合用于治疗，用于预防，治疗或改善响应刺激的中性粒细胞氧化性突发的反应的疾病或病症 的角质形成细胞IL-8释放或响应于坏死的诱导。
-
公开(公告)号：US09102687B2
公开(公告)日：2015-08-11
申请号：US13996989
申请日：2011-12-22
申请人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
发明人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
IPC分类号： C07D405/06 , C07D513/04 , C07C271/34 , C07C271/36 , C07C271/38 , C07D249/06 , C07D261/18 , C07D277/32 , C07D295/21 , C07D309/08 , C07D333/38 , C07D401/04 , C07D471/04 , C07D495/04 , C07D265/36 , C07D271/08 , C07D277/587 , C07D295/205 , C07D307/00 , C07D307/94
CPC分类号： C07D261/18 , A61K31/365 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/472 , A61K31/502 , A61K31/5375 , A61K31/538 , C07C271/34 , C07C271/36 , C07C271/38 , C07C2603/86 , C07D209/08 , C07D209/42 , C07D213/79 , C07D215/50 , C07D217/26 , C07D231/14 , C07D231/56 , C07D233/90 , C07D237/28 , C07D239/28 , C07D249/04 , C07D249/06 , C07D261/20 , C07D263/34 , C07D265/36 , C07D271/08 , C07D277/32 , C07D277/56 , C07D277/587 , C07D295/182 , C07D295/205 , C07D295/21 , C07D307/00 , C07D307/68 , C07D307/94 , C07D309/08 , C07D333/38 , C07D333/40 , C07D401/04 , C07D405/06 , C07D471/04 , C07D493/08 , C07D495/04 , C07D513/04
摘要： The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
摘要翻译： 本发明涉及通式I的化合物，其中R是任选被R 7取代的杂芳基; 或R是任选被R 8取代的杂环烷基或杂环烯基; 或R为X，其中X为-NR 11 R 12; 其药学上可接受的盐，水合物或溶剂合物，用于单独或与一种或多种其它药学活性化合物组合用于治疗，用于预防，治疗或改善响应刺激的中性粒细胞氧化性突发的反应的疾病或病症 的角质形成细胞IL-8释放或响应于坏死的诱导。
-
-
-
搜索结果
4 条记录 (耗时 0.024 秒)
